Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 4/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094121 | 0.74 | HSD11B1 (0.48) | KCNH2HSD11B1 | |
| SCHEMBL15259970 | 0.65 | OGA (0.43) | — | |
| SCHEMBL2759112 | 0.63 | RECQL (0.42) | OPRM1OPRK1KCNH2 | |
| SCHEMBL24367658 | 0.62 | RECQL (0.42) | OPRM1OPRK1KCNH2 | |
| SCHEMBL7993514 | 0.62 | RECQL (0.41) | OPRM1OPRK1KCNH2 | |
| SCHEMBL23475190 | 0.61 | RECQL (0.39) | OPRM1OPRK1KCNH2 | |
| SCHEMBL24387376 | 0.61 | ADRB2 (0.45) | OPRM1OPRK1KCNH2 | |
| SCHEMBL2040052 | 0.61 | RECQL (0.44) | OPRM1OPRK1KCNH2 | |
| SCHEMBL17000217 | 0.61 | RECQL (0.39) | OPRM1OPRK1KCNH2 | |
| SCHEMBL4330263 | 0.61 | RECQL (0.44) | OPRM1OPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | OPRM1 11/4885OPRK1 139/4885KCNH2 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.